Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.

Hoth Therapeutics, Inc., a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc. Mr. Robb Knie, Chief Executive Officer of Hoth, commented, “We are pleased to expand our partnership with Zylö and look forward to working together as our therapeutic for Lupus patients continues through the next phase of development. Read more >>